Singh, Jasvinder A. http://orcid.org/0000-0003-3485-0006
Cleveland, John D.
Funding for this research was provided by:
Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham (No number)
the resources and use of facilities at the Birmingham VA Medical Center, Birmingham, Alabama, USA (No number)
Article History
Received: 20 February 2019
Revised: 14 March 2019
Accepted: 18 March 2019
First Online: 29 March 2019
Compliance with ethical standards
:
: JAS has received consultant fees from Crealta/Horizon, Fidia, UBM LLC, Medscape, WebMD, the National Institutes of Health and the American College of Rheumatology. JAS owns stock options in Amarin pharmaceuticals and Viking therapeutics. JAS is a member of the executive of OMERACT, an organization that develops outcome measures in rheumatology and receives arms-length funding from 36 companies. JAS is a member of the Veterans Affairs Rheumatology Field Advisory Committee. JAS is the editor and the Director of the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis. JAS previously served as a member of the following committees: member, the American College of Rheumatology’s (ACR) Annual Meeting Planning Committee (AMPC) and Quality of Care Committees, the Chair of the ACR Meet-the-Professor, Workshop and Study Group Subcommittee, and the co-Chair of the ACR Criteria and Response Criteria subcommittee. DC has no conflicts to declare. There are no non-financial competing interests for any of the authors.
: The University of Alabama at Birmingham’s Institutional Review Board approved this study and all investigations were conducted in conformity with ethical principles of research. The IRB waived the need for informed consent for this study.
: No individual person’s data were presented in any form in this study and therefore no consent to publish is required.